

# Development of Novel Radiopharmaceutical for Prostate Specific Membrane Antigen Targeted Therapy

CellBion Co. Ltd.



ONCOLOGY	Phase 2
Product Type	Radiopharmaceutical (177Lu-labeled small chemical molecule)
Indication	Metastatic castration-resistant prostate cancer
Target	Prostate specific membrane antigen (PSMA)
MoA (Mechanism of Action)	Biding to PSMA → Endocytosis → Intracellular accumulation of 177Lu isotope → Radiation damages tumor cell DNA → Cell apoptosis
Competitiveness	<ul style="list-style-type: none"> <li>• Radiopharmaceutical for theragnostic targeting the prostate cancer</li> <li>• Excellent efficacy and safety due to high metabolic stability and rapid excretion through low albumin binding affinity</li> <li>• Companion diagnostic agent with highly similar structure for therapeutical drug</li> </ul>
Development Stage	Phase 2
Route of Administration	Parenteral-Intravenous